A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial
- 1 October 2010
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 20 (7) , 1137-1141
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II TrialsClinical Cancer Research, 2004
- Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology GroupInvestigational New Drugs, 2004
- Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor PatientsClinical Cancer Research, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)Biochemical Pharmacology, 1999
- Optimal flexible designs in phase II clinical trialsStatistics in Medicine, 1998
- Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)Biochemical Pharmacology, 1997
- Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.1997
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovaryAmerican Journal of Clinical Oncology, 1983